XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTSOn May 5, 2023, the Company was notified by FDA that they have completed the review of the Company's submission and have concluded that the clinical trial may be resumed. See Recent Developments for further discussion. From April 4, 2023 to May 11, 2023, the Company sold 527,672 ATM shares of its common shares with gross proceeds of approximately $1.3 million under the Sales Agreement.